Outcomes Underscore Need for New Agents to Treat Anaplastic Thyroid Carcinoma
Christine Dierks, MD, describes the prognosis of the anaplastic thyroid carcinoma and differentiated thyroid cancer populations.
Christine Dierks, MD, senior physician at the University Hospital Freiburg in Germany, describes the prognosis of the anaplastic thyroid carcinoma and differentiated thyroid cancer populations.
Dierks says that the prognosis is very poor for both patient populations but especially for those with anaplastic thyroid carcinoma. Poor outcomes are seen with patients who have anaplastic thyroid carcinoma even if they have combined therapy, which can include surgery and radiotherapy, followed by chemotherapy. In these patients, the life expectancy is about 4 to 5 months after therapy, according to Dierks.
In terms of survival, there is an exception for patients who had BRAF-positive disease because imatinib (Gleevec) is available for these patients. Dierks notes that for the other 80% of patients, the prognosis remains poor due to a lack of agents.
Post Hoc and Real-World Analyses Explore Benefit of Lenvatinib in DTC
December 5th 2024During a Case-Based Roundtable® event, Lori J. Wirth, discussed recent analyses that have developed a better understanding of the outcomes with lenvatinib in differentiated thyroid cancer in the second article of a 2-part series.
Read More
Anticipating Novel Options for the RAI-Refractory DTC Armamentarium
May 15th 2023In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.
Listen
